Description: SARS-CoV-2 (COVID-19) S1+S2 ECD (S-ECD), (Wild type,pre-fusion state) Recombinant Protein

Description: Autophagy, the process of bulk degradation of cellular proteins through an autophagosomic-lysosomal pathway is important for normal growth control and may be defective in tumor cells. It is involved in the preservation of cellular nutrients under starvation conditions as well as the normal turnover of cytosolic components (1,2). This process is negatively regulated by TOR (Target of rapamycin) through phosphorylation of autophagy protein APG1 (3). Another member of the autophagy family of proteins is APG7 which was identified in yeast as a ubiquitin-E1-like enzyme; this function is conserved in the mammalian homolog (4). In mammalian cells, APG7 is essential for autophagy conjugation systems, autophagosome formation, starvation-induced bulk degradation of proteins and organelles (5). It has been suggested that caspase-8 may alter APG7 levels and thus the APG7 program of autophagic cell death (6).

Description: Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Description: High sensitivity TMB Substrate especially designed for the microArray applications

Description: A polyclonal antibody against TAL1 (Ab-122). Recognizes TAL1 (Ab-122) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000

Description: A polyclonal antibody against TAL1 (Ab-122). Recognizes TAL1 (Ab-122) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000

Description: A polyclonal antibody against HIST1H3A (Ab-122). Recognizes HIST1H3A (Ab-122) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF, IP; Recommended dilution: WB:1:200-1:2000, IHC:1:1-1:10, IF:1:50-1:200, IP:1:200-1:2000

Description: A polyclonal antibody against HIST1H3A (Ab-122). Recognizes HIST1H3A (Ab-122) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF; Recommended dilution: WB:1:200-1:2000, IF:1:50-1:200

Description: A polyclonal antibody against HIST1H3A (Ab-122). Recognizes HIST1H3A (Ab-122) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IP; Recommended dilution: WB:1:200-1:2000, IP:1:200-1:2000

Description: A polyclonal antibody against HIST1H3A (Ab-122). Recognizes HIST1H3A (Ab-122) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IP; Recommended dilution: WB:1:200-1:2000, IP:1:200-1:2000

Description: A polyclonal antibody against HIST1H3A (Ab-122). Recognizes HIST1H3A (Ab-122) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IP; Recommended dilution: WB:1:200-1:2000, IHC:1:20-1:200, IP:1:200-1:2000

Description: Sum Formula: C20H36N8O5; CAS# [155149-79-4] net

Description: Sum Formula: C20H36N8O5; CAS# [155149-79-4] net